Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer (1996)
    Springer
    Cancer chemotherapy and pharmacology 38 (1996), S. 298-301 
    Details
    ISSN: 1432-0843
    Keywords: Key words Epithelial ovarian cancer ; Ifosfamide ; Mitoxantrone
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  Ifosfamide (IFX) and mitoxantrone (MXN) have been found to be effective against advanced epithelial ovarian cancer. The combination of these two agents has not yet been tested in this setting but seems to be rational, given the different action mechanisms of these drugs and their not completely overlapping side effects. Between June 1987 and November 1991, 37 patients with advanced ovarian carcinoma recurrent or refractory to primary cisplatin-based chemotherapy entered the study. Therapy consisted of MXN, given i.v. at 10 mg/m2 on day 1 and IFX given i.v. at 2,000 mg/m2 per day on days 1–3 with mesna. The cycles were repeated every 3 weeks. Four patients achieved a complete remission and three achieved a partial remission, for response rates of 18.9% [95% confidence interval (CI) 6.3–31.5%] in the whole sample and 38.8% (95% Cl 16.3–61.3%) in the subset of 18 patients responding to first-line cisplatin. No response was obtained in the remaining patients, whose disease was refractory to primary platinum-based chemotherapy. Clinically significant toxicity (WHO grades 3–4) included leukopenia in 46% of the patients and anemia in 32.5%. The non-hematologic toxicity was mild, except for reversible alopecia (57%) and nausea and vomiting (48.5%). This regimen seems attractive for patients who have either failed or not received platinum retreatment, especially when limiting neurotoxicity occurs. Further studies are warranted to establish the relative impact of both of these agents.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002800050486
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients (1997)
    Springer
    Neurological sciences 18 (1997), S. 73-79 
    Details
    ISSN: 1590-3478
    Keywords: Paclitaxel ; Neurotoxicity ; Distal axonopathy ; Platinum-compounds
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Sommario Il Paclitaxel appartiene a una nuova categoria di farmaci antiblastici la cui attività è legata alla capacità di interferire con il sistema dei microtubuli. La neurotossicità periferica è dovuta all'interferenza con i microtubuli assonali e all'alterazione del trasporto assonale. Allo scopo di definire le caratteristiche cliniche e neurofisiologiche di questa neuropatia sono stati studiati 23 pazienti sottoposti a terapia con Paclitaxel al dosaggio di 175 mg/mq. I risultati dello studio hanno mostrato un'elevata incidenza di neurotossicità periferica di grado moderato, valutata con una scala di neurotossicità basata sui segni e sintomi clinici e sui dati neurofisiologici. L'insieme dei dati permette di definire la neuropatia da Paclitaxel come una neuropatia sensitivo-motoria distale di tipo assonale, la cui reversibilità richiede ulteriori conferme.
    Notes: Abstract Paclitaxel is the prototype of a new class of chemotherapeutic agents with an antimitotic effect that is related to its ability to interfere with the microtubule system. It causes peripheral neurological toxicity by means of its activity on the axonal microtubules. To define the clinical and neurophysiological characteristics of paclitaxel neuropathy 23 patients undergoing paclitaxel therapy at a dose of 175 mg/m2 were studied. The patients were divided into two groups, with only one group receiving pretreatment with potentially neurotoxic drugs such as cisplatin and carboplatin. The results showed a high incidence of mild neurotoxicity in both groups. Treatment was discontinued due to severe neurotoxicity in only one patient pretreated with platinum-compounds. The clinical and neurophysiological data make it possible to define paclitaxel neurotoxicity as a distal axonal neuropathy with a summatory effect in patients pretreated with cisplatin; the possible reversibility of paclitaxel neurotoxicity requires further confirmation.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01999566
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...